دورية أكاديمية
Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach.
| العنوان: | Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach. |
|---|---|
| المؤلفون: | Lauder SN; Division of Infection and Immunity, Cardiff University School of Medicine, SIURI, Cardiff, UK. LauderSN@cardiff.ac.uk., Vanhaesebroeck B; UCL Cancer Institute, Paul O'Gorman Building, University College London, London, UK., Gallimore A; Division of Infection and Immunity, Cardiff University School of Medicine, SIURI, Cardiff, UK. |
| المصدر: | British journal of cancer [Br J Cancer] 2021 Aug; Vol. 125 (4), pp. 467-469. Date of Electronic Publication: 2021 Apr 06. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK Original Publication: London, Lewis. |
| مواضيع طبية MeSH: | Antigens, CD/*immunology , Class I Phosphatidylinositol 3-Kinases/*immunology , Immune Checkpoint Inhibitors/*pharmacology , Neoplasms/*drug therapy, Animals ; Drug Resistance, Neoplasm/drug effects ; Drug Synergism ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy ; Mice ; Neoplasms/immunology ; Tumor Microenvironment ; Xenograft Model Antitumor Assays ; Lymphocyte Activation Gene 3 Protein |
| مستخلص: | Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice. (© 2021. The Author(s).) |
| References: | Gallimore, A., Quezada, S. A. & Roychoudhuri, R. Regulatory T cells in cancer: where are we now? Immunology 157, 187–189 (2019). (PMID: 10.1111/imm.13088) Ahmad, S., Abu-Eid, R., Shrimali, R., Webb, M., Verma, V., Doroodchi, A., et al. Differential PI3Kδ signaling in CD4. Cancer Res. 77, 1892–1904 (2017). (PMID: 10.1158/0008-5472.CAN-16-1839) Chellappa, S., Kushekhar, K., Munthe, L.A., Tjønnfjord, G.E., Aandahl, E.M., Okkenhaug, K. et al. The PI3K p110δ isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function. J. Immunol. 202, 1397–1405 (2019). (PMID: 10.4049/jimmunol.1701703) Lim, E. L. & Okkenhaug, K. Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy. Immunology 157, 210–218 (2019). (PMID: 10.1111/imm.13082) Patton, D. T., Garden, O.A., Pearce, W.P., Clough, L.E., Monk, C.R., Leung, E. et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177, 6598–6602 (2006). (PMID: 10.4049/jimmunol.177.10.6598) Ali, K., Soond, D.R., Pineiro, R., Hagemann, T., Pearce, W., Lim, E.L. et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407–411 (2014). (PMID: 10.1038/nature13444) Lauder S. N., Smart, K., Kersemans, V., Allen, D., Scott, J., Pires, A. et al. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. J. Immunother. Cancer 8, 1–13 (2020). Workman, C. J. & Vignali, D. A. The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells. Eur. J. Immunol. 33, 970–979 (2003). (PMID: 10.1002/eji.200323382) Yano, H., Andrews, L. P., Workman, C. J. & Vignali, D. A. A. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity. Immunology 157, 232–247 (2019). (PMID: 10.1111/imm.13067) Woo, S. R., Turnis, M.E., Goldberg, M.V., Bankoti, J., Selby, M., Nirschl, C.J. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917–927 (2012). (PMID: 10.1158/0008-5472.CAN-11-1620) Sawyer, C., Sturge, J., Bennett, D.C., O'Hare, M.J., Allen, W.E., Bain, J. et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. Cancer Res. 63, 1667–1675 (2003). (PMID: 12670921) Xenou, L. & Papakonstanti, E. A. p110δ PI3K as a therapeutic target of solid tumours. Clin. Sci. (Lond.) 134, 1377–1397 (2020). (PMID: 10.1042/CS20190772) |
| معلومات مُعتمدة: | 15965 United Kingdom CRUK_ Cancer Research UK; 21200 United Kingdom CRUK_ Cancer Research UK; 25722 United Kingdom CRUK_ Cancer Research UK |
| المشرفين على المادة: | 0 (Antigens, CD) 0 (Immune Checkpoint Inhibitors) EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) EC 2.7.1.137 (PIK3CD protein, human) 0 (Lymphocyte Activation Gene 3 Protein) |
| تواريخ الأحداث: | Date Created: 20210407 Date Completed: 20211215 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC8368216 |
| DOI: | 10.1038/s41416-021-01285-1 |
| PMID: | 33824480 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1532-1827 |
|---|---|
| DOI: | 10.1038/s41416-021-01285-1 |